Engineering selective PI3Kγ inhibitors with antitumor and immunomodulatory potentials
Acta Pharmaceutica Sinica B · 2026-07 · 16 (7) · 4083-4102
DOI: 10.1016/j.apsb.2025.11.011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharmaceutica Sinica B, 2026-07. Verfasst von Yi Zuo und 14 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 6111…. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Sichuan Province Science and Technology Support Program, Science and Technology Department of Sichuan Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
PI3Kγ represents a promising therapeutic target for its pivotal role in macrophage recruitment and polarization and its significant association with tumor invasion and metastasis. In this study, a series of novel indole-based PI3Kγ selective inhibitors were generated by machine learning combined with molecular hybridization. Intriguingly, the representative IHA-5f displayed picomolar-level potency and highly selective inhibition to PI3Kγ relative to PI3Kα/β/δ. Moreover, IHA-5f manifested prominent anti-melanoma activity in vitro and in vivo with no detectable visceral toxicity. Mechanistically, IHA-5f efficiently suppressed tumor cell proliferation and migration, and induced apoptosis by suppressing the PI3Kγ/AKT/NF-κB signaling axis. Concurrently, it restrained the M2 polarization of tumor-associated macrophages, thereby augmenting the antitumor immune response. This study underscores the potential for PI3Kγ inhibitors as immunomodulators and direct antitumor agents.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
- Institute of Herbgenomics, Innovative Institute of Chinese Medicine and Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu 611137, China.
- Clinical Research Center, The First Affiliated Hospital of Shantou University Medical College, Shantou 515041, China.
- Department of Dermatology, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu 610075, China.
- Institute for Advancing Translational Medicine in Bone & Joint Diseases, School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 999077, China.
- Department of Physiology, School of Basic Medical Sciences, Shenzhen University, Shenzhen 518037, China.
Förderung
- Sichuan Province Science and Technology Support Program
- Science and Technology Department of Sichuan Province
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- Science and Technology Bureau of Chengdu
Zitieren
APA
Zuo, Y., Pu, Y., Liu, J., Chen, H., Chen, Y., Li, X., Wang, Y., Zhang, T., Cheng, H., Liu, J., Deng, Y., Cong, Z., Wang, M., Lu, J., & Chen, S. (2026). Engineering selective PI3Kγ inhibitors with antitumor and immunomodulatory potentials. Acta Pharmaceutica Sinica B, 16(7), 4083-4102. https://doi.org/10.1016/j.apsb.2025.11.011
Vancouver
Zuo Y, Pu Y, Liu J, Chen H, Chen Y, Li X, et al. Engineering selective PI3Kγ inhibitors with antitumor and immunomodulatory potentials. Acta Pharmaceutica Sinica B. 2026;16(7):4083-4102. doi:10.1016/j.apsb.2025.11.011
BibTeX
@article{Zuo2026,
author = {Zuo, Yi and Pu, Yiru and Liu, Jianan and Chen, Hongyu and Chen, Yao and Li, Xinlan and Wang, Yan and Zhang, Tingting and Cheng, Hongbin and Liu, Jin and Deng, Yun and Cong, Zhaotong and Wang, Maolin and Lu, Jun and Chen, Shilin},
title = {Engineering selective PI3Kγ inhibitors with antitumor and immunomodulatory potentials},
journal = {Acta Pharmaceutica Sinica B},
year = {2026},
volume = {16},
number = {7},
pages = {4083--4102},
doi = {10.1016/j.apsb.2025.11.011}
}
EUVIMED